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Abstract 
 
Introduction: 
Multiparametric-MRI (mp-MRI) is becoming an increasingly important diagnostic tool 
for prostate cancer. So far there has been little focus on the management of the 
indeterminate mp-MRI result. 
Objective: 
Describe the outcomes of a cohort of men who were rated as having an 
indeterminate mp-MRI result. 
Design, setting, and participants: 
Patients were identified retrospectively from a single UK centre between October 
2010 and January 2015. Patients were included if they had a Likert score of 3/5 on 
first MRI scan without any prior prostate biopsy. Patients were offered one of two 
initial management strategies. Strategy-One was an immediate targeted biopsy to 
the MRI lesion. Strategy-Two was a process of surveillance comprising of PSA 
(prostate specific antigen) monitoring and 6-12 months interval mp-MRI with biopsy 
on a for-cause basis. Cancer detection and treatment outcomes were compared 
between both strategies. 
Results and limitations: 
Of 168 patients, 73 (43%) men chose Strategy-One and 95 (57%) men chose 
Strategy-Two. The overall proportion of men with clinically significant cancer 
detected was 14% (23/168). The risk profile of cancer identified in the initial 
surveillance group was similar to that identified in the immediate biopsy group. 
Limitations of the study include the short follow-up. 
Conclusions: 
Men with an indeterminate mp-MRI were willing to forego immediate biopsy for a 
strategy of surveillance with PSA and interval mp-MRI. The risk profile of the cancers 
identified by both strategies appeared similar but many men avoided the risks, 
complications and costs of biopsy. Long-term results are awaited.  
Patient summary: 
In this report two approaches for an uncertain MRI result for clinically important 
prostate cancer were compared; immediate biopsy versus the strategy of 
surveillance with delayed biopsy if required. Delayed biopsy did not result in cancer 
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with adverse features being identified and many men benefitted from avoiding a 
biopsy and its complications. 
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Introduction (2425 words) 
 
The increasingly important role of multiparametric-MRI (mp-MRI) in relation to 
prostate cancer diagnosis and staging is being supported by the growing literature 
over recent years [1-3]. However, the literature has mostly confined itself to exploring 
the consequences of the lower and upper extreme test outputs – in other words, the 
negative and the positive scans. The clinical consequences of these test results are 
important. A negative result that is associated with a high negative predictive value 
for clinically significant disease could avoid many unnecessary biopsies [4]. A 
positive result, through its ability to assist in locating where within the gland the 
biopsy needles are deployed, can result in a greater proportion of men diagnosed 
with clinically significant disease [5]. 
 
So far very little attention has focused on the indeterminate results (grey zones) – an 
mp-MRI result that is neither fully positive nor fully negative. Current 
recommendations adopt confidence rating for the likelihood of having clinically 
significant cancer in which it is possible to derive a midpoint on an ordinal scale of 1 
through 5 corresponding to a 3/5 score - indeterminate for significant cancer [6-8]. 
Recent Level 1 evidence has shown that in a group of biopsy naïve men, a mp- MRI 
will have an indeterminate score in 28% of cases [3]. 
 
This cohort describes the outcome of men who were rated as having an 
indeterminate mp-MRI in order to better inform patients and clinicians for the shared 
decision-making process in the face of uncertainty. 
 
 
Material and Methods 
 
Patient population and study design 
 
Patients were identified retrospectively from a single UK centre. All men referred with 
clinical suspicion of prostate cancer based on raised PSA and/or positive family 
history and/or abnormal digital rectal examination and who had an mp-MRI of the 
prostate (between October 2010 and January 2015) as a first time assessment of 
prostate cancer risk were eligible. 
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The mp-MRI scan was scored by one of three expert prostate uro-radiologists for the 
likelihood of the presence of significant prostate cancer using the Likert scale (Score 
1, highly unlikely; score 2, unlikely; score 3, equivocal; score 4, likely to be present; 
score 5, highly likely to be present)[6, 7]). The radiologists had 10, 11 and 13 years 
of experience in prostate MRI reporting with each reporting >500 prostate mp-MRI 
scans per year. Likert scale was used as the study was designed prior to the latest 
Prostate Imaging Reporting and Data Systems (PI-RADS) publication [9] and 
previous studies have shown their performances to be comparable[8, 10]. Moreover, 
the Likert scale has been recently validated prospectively [3].All men who had an 
mp-MRI score of 3/5 were included in the study. 
 
These men, as part of routine care, were offered a choice between two management 
strategies that reflect the uncertainty associated with the indeterminate mp-MRI 
status. Strategy-One involved immediate targeted biopsy of the MRI lesion. Strategy-
Two comprised close surveillance by means of PSA monitoring and 6-12 months 
interval mp-MRI. Within Strategy-Two, the trigger for targeted biopsy during follow-up 
was any of the following: PSA progression, mp-MRI progression, mp-MRI non-
resolution or patient choice.  
 
 
MR equipment and image acquisition protocol 
 
An mp-MRI of the prostate was performed using a 3T magnet (MAGNETOM® Verio 
3T, Siemens Healthcare, Erlangen, Germany) equipped with a pelvic phased-array 
coil. The mp-MRI included T2-weighted imaging, dynamic contrast enhanced 
sequences (DCE) and diffusion weighted imaging (DWI): 
1. T2WI: axial and coronal planes; slice thickness, 3mm; TR, 5970ms; TE, 101ms; in 
plane resolution 0.625 x 0.625; matrix 320x320. 
2. DCE: slice thickness, 3 mm; TR, 4.06ms; TE, 1.46ms; flip angle, 10 degrees 
in plane resolution 1 x 1 mm; matrix 256x256. 
 
3. DWI sequences: slice thickness, 5 mm; TR, 4300ms; TE, 80ms; and b values of  
0, 100, 300, 800 and 1000 s/mm2 from which an apparent diffusion coefficient map 
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was generated. Also a high-b-value of 2000 s/mm2 was acquired with slice thickness 
of, 5 mm; TR, 7500ms; and TE, 79ms. 
 
Biopsy specifications and protocols 
 
Biopsy was performed in nearly all cases using a transperineal cognitive targeted 
sampling of the mp-MRI lesion +/- systematic transperineal template biopsy [11-14] 
by a single operator with an experience of >1000 cases.  
 
Analysis of the biopsies was carried out by one of two pathologists with 10 and 20 
years of experience. Clinically significant cancer was defined as any cancer with a 
Gleason score of 3+4 or greater or Gleason 6 with maximum cancer core length of 
≥4mm, as previously described [13]. 
 
 
Comparison of groups 
 
Cancer detection and treatment outcomes were compared between men choosing 
Strategy-One and men choosing Strategy-Two. The Statistical Package for the 
Social Sciences (SPSS 12.0.0 for windows) was used for all the data analyses. 
Differences between the median values of the patient groups were tested using the 
Mann-Whitney’s U test (Wilcoxon rank sum test) and for normally distributed data, an 
unpaired t-test was carried out. A p-value of less than 0.05 was considered to 
indicate a significant difference. 
 
Ethics 
This work has the approval of the Institutional Medical Advisory Committee.  
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Results 
 
A total of 178 men had an mp-MRI score of 3/5, but 10 men were excluded due to 
their choice of completing their treatment elsewhere after the mp-MRI. From the total 
of 168 patients, 73 (43%) underwent immediate biopsy (Strategy-One) and 95 (57%) 
choose the more conservative approach of surveillance with PSA and/or interval mp-
MRI with biopsy if required (Strategy-Two). 
 
The median age of men at first mp-MRI was 60 years (range, 36-85). Time to follow-
up ranged between 0-53 months in men within the surveillance group and 0-44 
months in the immediate biopsy group. The median follow-up time was 4 months in 
the immediate biopsy group and 6 months in the surveillance group. Men who chose 
immediate biopsy had a mean PSA of 4.9ug/l and a prostate volume of 49ml 
compared to 5.1ug/l and 46ml respectively among the Strategy-Two counterparts. 
(Table 1). 
 
In men who chose surveillance (Strategy-Two), just less than half (38/95, 40%) had 
one additional follow-up mp-MRI. Thirteen men underwent a second follow-up mp-
MRI, 5 men a third and 2 men a fourth. The remainder of men (37/95, 39%) 
continued on PSA surveillance alone. 
 
Ten men (10/95, 11%) who initially chose surveillance underwent biopsy during 
follow-up as a result of the triggers described above. Five men had progression on 
follow-up mp-MRI alone, 3 had a rise in PSA level alone and 2 had a combination of 
rising PSA level and progression on mp-MRI.  Median time between the mp-MRI and 
biopsy in these 10 men was 12 months. The median time to diagnosis of cancer was 
20 months in those men who chose initial surveillance compared to 1 month in men 
who chose immediate biopsy. 
 
The biopsy results of men who chose immediate biopsy (Strategy-One) are shown in 
Table 2. Thirty-three men (33/73, 45%) were diagnosed with prostate cancer. 
Nineteen men (19/73, 26%) had clinically significant cancer and 14 men (14/73, 
19%) had clinically insignificant cancer. None of the men had a dominant Gleason 
pattern 4 (>50% Gleason pattern 4) diagnosed and none had a maximum cancer 
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core length  ≥6mm. Of the remaining 40 men without cancer, 11 had biopsy tissue 
showing atrophy, 6 had atypical small acinar proliferation (ASAP), 9 had high-grade 
prostatic intraepithelial neoplasia (HGPIN) and 14 had acute or chronic inflammation. 
Figure 1 demonstrates MRI features of an indeterminate 3/5 score with inflammatory 
prostate tissue. 
 
In men who chose initial surveillance (Strategy-Two), 4 men (4/95, 4%) were 
diagnosed with clinically significant cancer during follow-up, all with Gleason 3+4 
prostate cancer. None of the men had dominant Gleason pattern 4 and none had a 
cancer core length ≥6mm. Of the remaining 6 men who underwent biopsy, none had 
cancer. One had biopsy tissue showing atrophy, 1 had ASAP and 4 had HGPIN 
(Table 3). 
 
Four of the 95 men (4%) in the surveillance group (Strategy-Two) had treatment with 
curative intent. Nine of the 73 men (12%) in the immediate biopsy group (Strategy-
One) had treatment with curative intent (Figure 2). 
 
Discussion 
 
Principal Findings 
 
In 168 men referred with clinical suspicion of prostate cancer (raised PSA and/or 
abnormal digital rectal examination and/or family history of prostate cancer) an 
indeterminate mp-MRI score resulted in 14% (23/168) of men with clinically 
significant cancer being identified. Of these 23 men, 19 were diagnosed in the 
immediate biopsy group (19/73, 26%) and 4 in the surveillance group (4/95, 4%) (p < 
0.001). No men had primary Gleason pattern 4 cancer or harboured high burden 
disease (maximum cancer core length ≥6mm) nor was extra-prostatic disease 
detected. This highlights that the majority of men with an indeterminate mp-MRI 
score do not harbour features of high-risk cancer. Many, however, did have florid 
non-cancerous changes in their prostates. 
 
When offered a choice of immediate biopsy (Strategy-One) or continued surveillance 
with PSA and/or interval MRI with delayed biopsy if required (Strategy-Two), the 
majority of men opted for surveillance and avoided biopsy. The minority of men who 
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underwent surveillance but required a delayed biopsy (10/95, 11%) were able to 
defer biopsy for 20 months and were diagnosed with cancers that were not dissimilar 
to the highest risk cancers in the immediate biopsy group, whilst still remaining 
eligible for curative treatment. 
 
Clinical and research implications 
 
To our knowledge, this is the largest reported cohort of men exclusively with 
indeterminate mp-MRIs, in which we introduce alternative management strategies 
that other clinicians may wish to consider. 
 
The majority of men with a mp-MRI score of 3/5 chose surveillance over immediate 
biopsy. This highlights that many men are willing to forego biopsy in the face of 
uncertainty and that surveillance in men with a 3/5 or “indeterminate” score is a 
feasible strategy choice for patients. This may be related to the invasiveness of the 
procedure, associated pain and complications and the option of a reasonable 
alternative. In the era of quinolone-resistant bacteria [15], avoiding biopsy where 
possible is a priority in the field of prostate cancer diagnosis. This may also reduce 
the burden of over-diagnosis and over-treatment which is a significant problem in 
prostate cancer management [16]. 
 
A strategy of surveillance avoided a biopsy in the majority of the group (85/95, 89%). 
Close monitoring allowed the progression of suspicious lesions being detected, 
determined by MRI or PSA rises, in which case a biopsy would subsequently be 
required. Those who eventually underwent biopsy, delayed this for 20 months. This 
is similar to a strategy that many institutions adopt for patients on active surveillance. 
The advantages also translate to men on active surveillance who could undergo 
biopsy on basis of one of these triggers rather than at routine time points. 
 
When comparing the cancers detected in men undergoing the two strategies, those 
cancers identified in men undergoing surveillance and delayed biopsy were not 
dissimilar to the highest risk cancers in the immediate biopsy group. Delaying biopsy 
for a median of 20 months from initial MRI in the surveillance group did not render 
any of the 4 men with cancer ineligible for curative treatment. 
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The majority of men immediately undergoing biopsy had non-cancerous findings 
(40/73, 55%) such as atrophy, acute/chronic inflammation, HGPIN or ASAP, which 
may shed light on common histopathological features of lesions scored 3/5 on mp-
MRI. Whether this inflammation is causally related to the cancer or independent 
needs to be the subject of future research. Correlation of the histopathological 
results of men with indeterminate MRI lesions is important in this respect. 
 
This data can inform the shared decision-making process for how to manage men 
with indeterminate MRIs and clinicians may wish to consider these strategies for 
management of their patients. For an option of surveillance, patients should be made 
aware that regular PSAs (every 3-6 months) and a repeat MRI after 12 months are 
recommended in order to identify any progressive disease if present. It should be 
emphasised that the long-term outcomes of the results of such a strategy are 
needed before routine recommendations can be made but clinicians and patients 
should be aware of the possibility of alternative management strategies, which they 
could benefit from. Early results would suggest that men are not at risk when 
adopting a surveillance approach at first, since the cancers detected were not 
dissimilar to the highest risk cancers in the immediate biopsy group. 
 
The conservative strategy has some advantages, namely an average delay in biopsy 
of 20 months in those who eventually underwent biopsy during follow-up and the 
avoidance of a biopsy in the majority of the group (85/95, 89%). This is a particularly 
important advantage for patients and healthcare economics.  
 
Future work should focus on the long-term outcomes of these men and identify 
methods to cut-across the mid-point to score the MRI as normal (no biopsy required) 
or abnormal (biopsy required). Biomarkers may play a role [17]  as will PSA density 
[18]. Developments in MRI, particularly in the diffusion [19], are also promising as 
these should improve both sensitivity and specificity for clinically significant disease. 
 
Limitations 
 
A limitations of this study include its retrospective observational nature, short-term 
follow-up and small sample size. However, this is a unique 5-year data set in men 
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with no prior biopsy, reflecting real patient choice and subsequent outcomes for men 
with an indeterminate MRI. This may therefore offer value to clinicians in managing 
men referred with clinical suspicion of prostate cancer. Furthermore, given the 
increasing use of mp-MRI in the diagnosis of prostate cancer, discussion of the 
surveillance strategy is appropriate now, as it may be immediately beneficial to 
patients by avoiding the risks, discomfort and complications of biopsy. The long-term 
outcomes of men treated with this strategy, however, remain to be seen. We 
acknowledge the verification bias provided by not all men having a regimented 
universal biopsy regime but these data form the foundation for this strategy to be 
investigated in an interventional trial design. 
 
We also acknowledge that mp-MRI conduct and reporting is subject to a learning 
curve [20]  and that indeterminate scores may differ from experienced and less 
experienced radiologists. Other centres should be aware of this prior to considering 
such a strategy for men with indeterminate MRIs and we would advocate audit and 
publication of individual centre results to ensure that performance is similar to those 
published in the literature. 
 
Conclusion  
 
Men with an indeterminate mp-MRI are willing to forego immediate biopsy for a 
strategy of close surveillance with MRI and regular PSAs. Men undergoing 
surveillance who ultimately have a biopsy during follow-up due to specific triggers, 
have cancer similar in risk profile to that identified in men undergoing immediate 
biopsy, for which they can still be treated with curative intent. This surveillance 
strategy will result in fewer men needing to undergo biopsy, benefiting both patients 
and healthcare systems. Long-term results of such a strategy are awaited. 
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Figures and Tables 
 
Table 1. Patient’s specifications divided by Strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSA: Prostate specific antigen, SD: Standard deviation,*significant outcome 
 
 
 
Table 2. Biopsy results of men who chose Strategy-One (Immediate biopsy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASAP: Atypical small acinar proliferation, PIN: Prostatic intraepithelial neoplasia, PSA: Prostate 
specific antigen. 
  
 
 MRI 
Surveillance  
(n = 95, 57%) 
Immediate 
Biopsy 
(n = 73, 43%) 
p-value 
Age, mean (SD), y 60 (9.8) 60 (7.1) 0.811 
PSA, median (IQR), 
ug/l 
4.9 (0.2-34) 5.1 (0.7-22) 0.564 
Prostate volume, 
mean (SD), ml 
49 (24.3) 46 (21.6) 0.384 
Time between MRI 
and biopsy, median 
(IQR), m 
12 (3-35) 1 (0-6) <0.001* 
 
Time between MRI 
and cancer 
diagnosis, median 
(IQR), m 
20 (3-35) 1 (0-2)  
<0.001* 
Follow-up time, 
median (IQR), m 
6 (0-44) 4 (0-53) 0.157 
Immediate Biopsy (n = 73) 
 Malignant: 
Gleason 3+3 n (%) 21 (29%) 
Gleason 3+4 n (%) 12 (16%) 
 Benign: 
Atrophy n (%) 11 (15%) 
Acute (chronic) 
inflammation n (%) 
14 (19%) 
ASAP n (%) 6 (8%) 
High grade PIN n (%) 9 (12%) 
Maximum cancer core 
length, median (IQR), mm 
3.0 (0.5-6.0) 
Gleason 4 Pattern, median 
(IQR), % 
20 (10-40) 
Clinically significant cancer 
n (%) 
19 (26%) 
Treatment n (%) 9 (12%) 
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Table 3. Biopsy results of men undergoing Strategy-Two (initial surveillance) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ASAP: Atypical small acinar proliferation, PIN: Prostatic intraepithelial neoplasia, PSA: Prostate 
specific antigen. 
 
  
Initial surveillance (n = 10) 
 Malignant: 
Gleason 3+3 n (%) 0 (0%) 
Gleason 3+4 n (%) 4 (40%) 
 Benign: 
Atrophy n (%) 1 (10%) 
Acute (chronic) 
inflammation n (%) 
0 (0%) 
ASAP n (%) 1 (10%) 
High grade PIN n (%) 4 (40%) 
Maximum cancer core 
length, median (IQR), mm 
8.5 (5.0-12.0) 
Gleason 4 Pattern, median 
(IQR), % 
20 (10-25) 
Clinically significant cancer 
n (%) 
4 (<1%)  
Treatment n (%) 4 (<1%) 
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Figure 1 
 
Figure 1. Illustration of the peripheral zone of a 59 year old patient presenting a PSA of 7.4 
µg/L which was scored 3 out of 5 on the multiparametric MRI of the prostate. 
Diffuse low signal is seen in the PZ on T2 weighted imaging from 2 to 8 o'clock (arrowheads).  
Two focal lesions with reduced ADC are seen on the ADC map as shown by the arrows, one of which 
shows a focus of restricted diffusion (high signal intensity) on DWI b2000 at 7 o'clock as indicated 
(dotted-arrow).  
On DCE imaging, diffuse and almost continuous enhancement is seen bilaterally from 1 to 10 o'clock 
along with some capsular enhancement. There is an equivocal focus of enhancement corresponding 
to the lesion with reduced ADC and high signal intensity on b2000 at 7 o'clock (dotted-arrow). This 
lesion was targeted at biopsy which showed inflammatory tissue.  
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Figure 2 
 
 
 
Figure 2. Flow chart of the outcomes from different strategies in the management of men with 
indeterminate mp-MRIs. 
This flow chart represents the clinical outcomes and type of treatment from patients who either 
underwent Strategy-One or Two. Strategy-One was associated with immediate targeted biopsy of the 
MRI lesion and Strategy-Two was associated with close surveillance comprising PSA monitoring 
and/or 6-12 month interval mp-MRI with biopsy if required. 
DRE: Digital rectal examination, HIFU: High intensity focused ultrasound, PSA: Prostate specific 
antigen, RP: Radical Prostatectomy. 
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